Ireland - English - HPRA (Health Products Regulatory Authority)

crucell italy s.r.l. - a/california/7/2009 (h1n1)pdm09-derived strain used (nymc x-181) a/victoria/361/2011 (h3n2)-like strain used (nymc x-223a) derived from a/texas/50/2012 b/massachusetts/02/2012 derived strain used (nymc bx-51b) - suspension for injection - 15 microgram

Ireland - English - HPRA (Health Products Regulatory Authority)

crucell italy s.r.l. - hepatitis a virus (strain rg-sb) - suspension for injection

Ireland - English - HPRA (Health Products Regulatory Authority)

crucell italy s.r.l. - a/california/7/2009 (h1n1) - derived strain used nymc x-181 reass a/california/7/2009 (h1n1) - derived strain used nymc x-181 reass b/brisbane/60/2008 - like strain (b/brisbane/60/2008) - suspension for injection - 15 microgram

Ireland - English - HPRA (Health Products Regulatory Authority)

crucell italy s.r.l. - hepatitis a virus (strain rg-sb) - suspension for injection - %v/v

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - hepatitis a virus inactivated - emulsion for injection

Singapore - English - HSA (Health Sciences Authority)

johnson & johnson pte. ltd. - influenza virus a/california/7/2009 (h1n1)- like strain - injection, suspension - 15mcg haemagglutinin /0.5 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

csl limited - salmonella typhi -

United States - English - NLM (National Library of Medicine)

rebel distributors corp - salmonella enterica subsp. enterica serovar typhi (unii: 760t5r8b3o) (salmonella enterica subsp. enterica serovar typhi - unii:760t5r8b3o) - salmonella enterica subsp. enterica serovar typhi 2 [cfu] - vivotif (typhoid vaccine live oral ty21a) is indicated for immunization of adults and children greater than 6 years of age against disease caused by salmonella typhi . routine typhoid vaccination is not recommended in the united states of america. selective immunization against typhoid fever is recommended for the following groups: 1) travelers to areas in which there is a recognized risk of exposure to s. typhi , 2) persons with intimate exposure (e.g. household contact) to a s. typhi carrier, and 3) microbiology laboratorians who work frequently with s. typhi (7). there is no evidence to support the use of typhoid vaccine to control common source outbreaks, disease following natural disasters or in persons attending rural summer camps. not all recipients of vivotif will be fully protected against typhoid fever. vaccinated individuals should continue to take personal precautions against exposure to typhoid organisms. the vaccine will not afford protection against species of salmonella other than salmonella

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmabroker sales ltd - bacillus calmette-guerin (8 to 26 mvu/ml sub-strain 1077) - powder for injection - active: bacillus calmette-guerin (8 to 26 mvu/ml sub-strain 1077) excipient: dextran glucose octoxinol